REFERENCES
- Bisogno G, Riccardi R, Ruggiero A, Arcamone G, Prete A, Surico G, et al. Phase II study of a protracted irinotecan sched-ule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006; 106 (3): 703–707.
- Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Lucht-man-Jones L, et al. A phase I study of irinotecan in pediatric Patients: a pediatric oncology group study. Clin Cancer Res 2001; 7: 32–37.
- Bomgaars L, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer 2006; 46: 50–55.
- Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, et al. Direct translation of a protracted irinote-can schedule from a xenograft model to a phase I trial in chil-dren. J Clin Oncol 1999; 17: 1815–1824.
- Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 2003; 21: 3844-3852.
- Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997; 33: 245–259.
- Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, et al. Phase I and pharmacologic study of irinote-can administered as a 96- hour infusion weekly to adult cancer patients. J Clin Oncol 2000; 18: 659–667.
- Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity. A pharmacogenetic analysis. Cancer Res 2000; 60: 6921–6926.
- Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, et al. The UDP glycosyltransferase gene super-family: recommended nomenclature update based on evolution-ary divergence. Pharmacogenetics 1997; 7: 255–269.
- Takeuchi K, Kobayashi Y, Tamaki S, Ishihara T, Maruo Y, Araki J, et al. Genetic polymorphisms of bilirubin uridine diphos-phate-glucuronosyltransf erase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol 2004; 19: 1023–1028.
- Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Can-cer Treat Rev 2008; 34 (7): 656–669.
- de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, Sparreboom A, et al. Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 2008; 84 (2): 254–262.
- Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27 (16): 2604–2614.
- Liu CY, Chen PM, Chiou T, Liu J, Lin JK, Lin TJ,et al. UGT1A1*28 polymorphism predicts Irinotecan-induced severe toxicities without affecting treatment outcome and survival in Patients with metastatic colorectal carcinoma. Cancer. 2008; 112: 1932-1940.
- Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, et al. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the chil-dren's oncology group. Cancer Chemother Pharmacol 2008; 62 (6): 1027–1037.
- Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in Patients receiving low-dose irinotecan. J Clin Oncol. 2007; 25 (18): 2594–2600.
- Yamamoto M, Kurita A, Asahara T, Takakura A, Katono K, Iwasaki M, et al. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rat. Oncol Rep 2008; 20 (4): 727–730.
- Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 2002; 62 (1): 179–187.
- Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT41. Cancer Res. 2002; 62 (20): 5778–5784.